Quizartinib
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Acute Myeloid Leukemia (AML)
Conditions
Acute Myeloid Leukemia (AML)
Trial Timeline
Nov 5, 2018 → Mar 3, 2022
NCT ID
NCT03723681About Quizartinib
Quizartinib is a phase 1 stage product being developed by Daiichi Sankyo for Acute Myeloid Leukemia (AML). The current trial status is completed. This product is registered under clinical trial identifier NCT03723681. Target conditions include Acute Myeloid Leukemia (AML).
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (5)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06772246 | Phase 1 | Completed |
| NCT06740799 | Phase 1 | Recruiting |
| NCT04473664 | Phase 1 | Completed |
| NCT03723681 | Phase 1 | Completed |
| NCT02984995 | Phase 2 | Completed |
Competing Products
20 competing products in Acute Myeloid Leukemia (AML)